movo

Migration, Crosslink

📖

movo

active

wiki page Created: 2026-04-02T07:20:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-movo

📖 Wiki Page

company3666 wordssynced 2026-04-02

MOVO

Overview

flowchart TD companies_movo["movo"] style companies_movo fill:#4fc3f7,stroke:#333,color:#000 companies_movo_0["Corporate Profile"] companies_movo -->|"includes"| companies_movo_0 style companies_movo_0 fill:#81c784,stroke:#333,color:#000 companies_movo_1["Mission and Vision"] companies_movo -->|"includes"| companies_movo_1 style companies_movo_1 fill:#ef5350,stroke:#333,color:#000 companies_movo_2["Technology Platform"] companies_movo -->|"includes"| companies_movo_2 style companies_movo_2 fill:#ffd54f,stroke:#333,color:#000 companies_movo_3["Core Technology: Markerless Motion Capture"] companies_movo -->|"includes"| companies_movo_3 style companies_movo_3 fill:#ce93d8,stroke:#333,color:#000 companies_movo_4["Technical Specifications"] companies_movo -->|"includes"| companies_movo_4 style companies_movo_4 fill:#4fc3f7,stroke:#333,color:#000 companies_movo_5["Software Architecture"] companies_movo -->|"includes"| companies_movo_5 style companies_movo_5 fill:#81c784,stroke:#333,color:#000

...

MOVO

Overview

Mermaid diagram (expand to render)

MOVO is a digital health company developing rehabilitation and movement tracking technology for neurological conditions, with primary applications in [Parkinson's disease](/diseases/parkinsons-disease) (PD) and post-stroke recovery. Founded in 2017 and headquartered in the United States, MOVO creates technology solutions that enable clinicians and patients to track, analyze, and improve movement quality through markerless motion capture and digital therapeutics["@movo"].

The company addresses a critical gap in neurological rehabilitation: the lack of objective, quantitative measurement tools for tracking movement quality between clinical visits. Traditional assessment relies heavily on subjective clinical ratings, making it difficult to detect subtle changes in motor function or evaluate the effectiveness of therapeutic interventions over time. MOVO's platform bridges this gap by providing continuous, objective movement data that can inform clinical decision-making and empower patients to participate actively in their rehabilitation.

Corporate Profile

| Attribute | Details |
|-----------|---------|
| Headquarters | United States |
| Founded | 2017 |
| Focus | Digital therapeutics, movement rehabilitation |
| Target Conditions | Parkinson's disease, stroke rehabilitation, movement disorders |
| Business Model | B2B (clinicians, healthcare systems) + B2C (patients) |

Mission and Vision

MOVO's mission is to make high-quality rehabilitation accessible to anyone affected by movement disorders. The company envisions a future where every patient with Parkinson's disease has access to tools that enable them to monitor their progress, stay motivated, and communicate effectively with their healthcare providers about their condition.

The company's approach recognizes that Parkinson's disease is a progressive condition requiring ongoing management, and that rehabilitation is most effective when it is consistent, personalized, and data-driven. By combining sophisticated technology with evidence-based therapeutic protocols, MOVO aims to transform how movement disorders are managed in both clinical and home settings.

Technology Platform

Core Technology: Markerless Motion Capture

MOVO's foundational technology is a markerless motion capture system that uses computer vision and depth sensors to track human movement without requiring markers, sensors, or specialized clothing worn by the user. This approach represents a significant advancement over traditional motion capture systems that require expensive equipment, technical expertise, and time-consuming setup procedures.

The system works by:

Depth Sensing: Using depth cameras (similar to those found in modern smartphones and gaming consoles) to capture three-dimensional information about the user's body position

Pose Estimation: Applying machine learning models to identify key body landmarks (joints, limbs) in real-time

Movement Analysis: Comparing observed movement patterns against established norms and baseline measurements

Feedback Generation: Providing visual, auditory, or haptic feedback to guide therapeutic exercises

The markerless approach offers several advantages for clinical use:

Accessibility: No specialized equipment beyond a standard camera and computing device
Scalability: Can be deployed in clinic, home, or community settings
Patient Comfort: Eliminates the friction of wearing sensors or markers
Cost-effectiveness: Reduces infrastructure requirements compared to optical motion capture systems[@motion_capture_accuracy]

Technical Specifications

The MOVO platform operates on consumer-grade hardware:

| Component | Specification |
|-----------|---------------|
| Camera | Standard RGB-D depth camera (e.g., Intel RealSense, Azure Kinect) |
| Processing | Edge computing on local device |
| Frame Rate | 30-60 Hz |
| Latency | <100 ms for real-time feedback |
| Accuracy | Comparable to marker-based systems for gross movements |
| Platform | Cloud-connected, browser-based interface |

Software Architecture

The MOVO software stack includes several key components:

MOVO Capture: The core motion tracking module that processes camera input and extracts body pose data

MOVO Analyze: Post-processing and analysis tools for clinicians to review patient performance

MOVO Coach: The patient-facing application that guides therapeutic exercises with real-time feedback

MOVO Connect: Integration layer for connecting to electronic health records and telehealth platforms

Validation and Accuracy

The accuracy of markerless motion capture systems for clinical movement analysis has been extensively validated. Studies have demonstrated that markerless systems can achieve accuracy within 2-5 centimeters for key joint positions, which is sufficient for clinical assessment of gross motor function in neurological conditions[@motion_capture_accuracy][@computer_vision_rehab].

Research has shown that markerless systems are particularly suitable for:

Gait analysis in Parkinson's disease
Balance assessment
Range of motion measurement
Movement quality scoring

While markerless systems may not match the precision of marker-based optical systems for detailed biomechanical analysis, they offer sufficient accuracy for clinical decision-making and have the advantage of being usable in real-world settings rather than laboratory environments.

Products and Services

MOVO Motion System

The MOVO Motion System is a comprehensive digital rehabilitation platform that combines motion tracking with guided exercise programming. The system is designed for use in multiple settings:

Clinical Deployment

In-clinic assessment and therapy sessions
Outcome measurement for tracking patient progress
Integration with existing clinical workflows
HIPAA-compliant data storage and handling

Home-Based Rehabilitation

Remote patient monitoring
Guided exercise programs for home practice
Progress tracking and reporting
Integration with telehealth sessions

Research Applications

Standardized movement assessment protocols
Objective outcome measures for clinical trials
Long-term monitoring of disease progression

MOVO PD Program

The Parkinson's disease-specific program includes specialized modules addressing the motor symptoms most commonly affecting PD patients:

Gait Training Module

Gait abnormalities are among the most disabling features of Parkinson's disease, including:

Shuffling: Shortened stride length and reduced foot clearance
Festination: Progressively shortening steps during walking
Freezing of gait: Sudden, temporary inability to initiate or continue movement
Reduced arm swing: Decreased contralateral arm movement during walking

The MOVO gait training module includes:

Gait analysis: Objective measurement of stride length, velocity, cadence, and foot clearance
Visual cues: Real-time feedback to improve step length and timing
Rhythmic auditory stimulation: Music-based cueing to improve gait rhythm
Progressive exercise protocols: Structured programs that adapt to patient ability

Research has demonstrated that cueing strategies, including visual and auditory cues, can significantly improve gait in PD patients[@gait_training]. MOVO's platform provides multiple cueing modalities that can be customized to individual patient preferences and needs.

Balance Training Module

Balance impairment is a major contributor to fall risk in Parkinson's disease. The MOVO balance training module addresses:

Postural stability assessment: Quantitative measurement of sway and balance performance
Balance exercises: Progressive protocols from static to dynamic balance challenges
Fall prevention education: Training in safe movement strategies
Progress tracking: Objective measurement of balance improvement over time

Studies have shown that balance training is effective in improving postural stability in PD, with benefits including reduced fall frequency and improved confidence in daily activities[@balance_training_pd][@fall_prevention].

Strength Training Module

Muscle weakness and reduced endurance contribute to functional decline in Parkinson's disease. The strength training module includes:

Progressive resistance exercises: Programs targeting major muscle groups
Form feedback: Real-time guidance on exercise technique
Dosing management: Controlled intensity and volume based on patient status
Recovery monitoring: Integration of rest periods based on fatigue levels

Exercise has been shown to have neuroprotective effects in PD models, potentially through mechanisms including increased brain-derived neurotrophic factor (BDNF) signaling and improved mitochondrial function[@dopamine_exercise][@neuroplasticity_exercise].

Flexibility Module

Rigidity and reduced range of motion are common PD symptoms that affect function. The flexibility module includes:

Stretching protocols: Guided stretching exercises for key muscle groups
Range of motion tracking: Objective measurement of joint mobility over time
Relaxation techniques: Breathing and movement strategies for managing rigidity

Remote Monitoring Capabilities

MOVO enables clinicians to monitor patient progress between visits through:

Automated session tracking: Recording completed exercises and patient-reported outcomes
Alert systems: Notifications when patient performance declines or falls
Progress reports: Automated summary reports for clinical review
Telehealth integration: Seamless transition to virtual visits when needed

Long-term remote monitoring has become increasingly important in Parkinson's disease management, where symptom fluctuation and disease progression require ongoing attention[@remote_monitoring].

Clinical Evidence and Rationale

Exercise in Parkinson's Disease

The role of exercise in Parkinson's disease management has been extensively documented, with high-quality evidence supporting its benefits across multiple domains:

Motor Function
Multiple systematic reviews and meta-analyses have demonstrated that exercise improves motor function in PD. A 2021 review found that exercise interventions significantly improve Unified Parkinson's Disease Rating Scale (UPDRS) motor scores, with effects comparable to some pharmacological interventions[@lsbig2021].

Balance and Falls
Balance-specific training reduces fall risk and improves postural stability. A systematic review found that balance training programs reduce falls by 40-50% in community-dwelling older adults, with similar benefits observed in PD populations[@fall_prevention].

Quality of Life
Exercise improves both physical and psychological aspects of quality of life in PD. Benefits include improved mood, reduced fatigue, and enhanced ability to perform daily activities[@outcome_measures].

Neuroplasticity
Evidence from animal models and human neuroimaging studies suggests that exercise promotes neuroplasticity in the Parkinson's disease brain. Structural MRI studies have shown increased brain volume in exercise-trained PD patients compared to controls, suggesting exercise may slow neurodegeneration[@mri_exercise].

Digital Therapeutics Evidence

The field of digital therapeutics for Parkinson's disease has grown rapidly, with multiple studies demonstrating the efficacy of technology-enabled rehabilitation:

Home-Based Exercise
Randomized controlled trials have shown that home-based exercise programs are non-inferior to in-person therapy for improving motor function in PD[@dtx_efficacy]. Digital platforms enable higher exercise dose (more total exercise time) while maintaining clinical outcomes.

Telehealth Effectiveness
Telehealth-delivered physical therapy has been validated as effective for PD, with studies showing equivalent outcomes to in-person delivery for both assessment and intervention[@tele PT efficacy].

Adherence Benefits
Digital health interventions improve exercise adherence through features including goal-setting, progress feedback, reminders, and gamification. Studies show that digital platforms can increase exercise adherence by 30-50% compared to traditional approaches[@gamification_adherence].

Continuous Monitoring
Remote monitoring enables detection of subtle changes that might be missed in between clinical visits, allowing for earlier intervention and treatment adjustment[@remote_monitoring].

Clinical Applications

Parkinson's Disease Management

MOVO supports comprehensive PD management across the disease trajectory:

Early Stage

Baseline movement assessment
Education and self-management tools
Exercise prescription for maintenance
Goal-setting for physical activity

Mid Stage

Intensive gait and balance training
Fall prevention programming
Management of motor fluctuations
Integration with medication timing

Advanced Stage

Caregiver-supported exercise programs
Wheelchair-seated exercise options
Monitoring for complications
Palliative rehabilitation approaches

Post-Stroke Rehabilitation

The platform also supports post-stroke rehabilitation, addressing:

Hemiparesis recovery
Gait retraining
Balance rehabilitation
Upper extremity function

Other Movement Disorders

MOVO's technology is applicable to other neurological conditions affecting movement:

Multiple sclerosis
Huntington's disease
Ataxias
[Dystonia](/diseases/dystonia)

Clinical Settings

The platform is designed for deployment in:

| Setting | Application |
|---------|-------------|
| Outpatient neurology clinics | Assessment and therapy |
| Physical therapy departments | Movement analysis and training |
| Home health | Remote monitoring and coaching |
| Skilled nursing facilities | Maintenance exercise programs |
| Research settings | Standardized outcome measures |
| Telehealth | Virtual rehabilitation sessions |

Competitive Landscape

MOVO operates in the digital therapeutics and movement assessment market, competing with several other companies and approaches:

| Company/Product | Approach | Key Features |
|----------------|----------|---------------|
| Kaia Health | Digital therapeutics | Exercise programs, respiratory training |
| Hinge Health | MSK digital therapeutics | Exercise coaching, education |
| Pear Therapeutics | Prescription digital therapeutics | FDA-cleared PD program |
| NeuroPace | Neurostimulator | Responsive neurostimulation |
| Rune Labs | Parkinson's platform | Wearable integration, symptom tracking |
| Personalized Parkinson's Project | Research platform | Big data, precision medicine |

MOVO differentiates through:

Markerless motion capture: No wearables required for basic functionality
Clinical-grade accuracy: Validated measurement equivalent to gold-standard systems
Comprehensive rehabilitation: Full exercise program, not just tracking
Flexible deployment: Works in clinic, home, or research settings

Market Opportunity

The addressable market for MOVO includes:

Parkinson's Disease Market

10 million people worldwide with PD
$6 billion annual market for PD therapeutics
Growing emphasis on exercise as disease-modifying intervention
Increasing telehealth adoption post-pandemic

Digital Rehabilitation Market

$15 billion+ market for digital health rehabilitation
25%+ annual growth rate
Strong payer interest in value-based care
Regulatory support for digital therapeutics

Telehealth Market

Explosive growth during COVID-19 pandemic
Continued expansion of virtual care options
Reimbursement parity with in-person services

Regulatory Status

FDA Considerations

Digital health products for rehabilitation may fall under various FDA regulatory pathways:

Software as Medical Device (SaMD): Classification depends on intended use
Digital Therapeutics: May qualify for FDA Center for Drug Evaluation and Research (CDER) approval
General Wellness: Products making only general claims may not require FDA clearance

MOVO is pursuing appropriate regulatory pathways to enable broad commercialization:

510(k) pathway: For cleared medical devices with predicate products
De novo classification: For novel device types without predicates
FDA Digital Health Center of Excellence: Engagement for regulatory guidance

Reimbursement

Reimbursement is critical for commercial success:

CPT codes: Physical therapy evaluation and treatment codes applicable
Remote therapeutic monitoring (RTM): New codes for remote rehabilitation monitoring
Value-based contracts: Population-based payment models favoring digital health

The evolution of reimbursement codes for digital health services has created new opportunities for platforms like MOVO to be integrated into standard care pathways.

International Regulatory

CE Marking: For European Union market access
Health Canada: Canadian regulatory clearance
TGA: Australian Therapeutic Goods Administration registration

Technology Development Roadmap

Current Capabilities

Markerless motion capture for gross motor assessment
Guided exercise programs for PD and stroke
Remote monitoring for clinician oversight
Telehealth integration

Near-Term Development

Enhanced AI for movement quality assessment
Expanded exercise library with condition-specific protocols
Integration with wearable sensors for comprehensive monitoring
Mobile app for patient engagement

Long-Term Vision

Predictive analytics for disease progression
Personalized exercise recommendations based on individual characteristics
Integration with pharmaceutical and device therapies
Global access through multilingual platform

Partnerships and Collaborations

MOVO collaborates with multiple stakeholders in the Parkinson's disease ecosystem:

Academic Partnerships

Parkinson's disease research centers: Clinical validation studies
Physical therapy schools: Training and education programs
Engineering departments: Technology development collaboration

Healthcare System Partnerships

Neurology practices: Implementation and clinical workflow integration
Physical therapy networks: Standardized assessment and treatment protocols
Integrated delivery networks: Population health management

Industry Partnerships

Medical device companies: Integration with complementary products
Pharmaceutical companies: Companion digital therapies for PD drugs
Wearable technology: Data integration with smart watches and activity trackers

Research Collaborations

Clinical trials: Objective outcome measures for intervention studies
Observational studies: Long-term disease progression monitoring
Registry participation: Contribution to Parkinson's disease databases

Clinical Validation

MOVO's technology has been validated through multiple research studies:

Accuracy Studies

Comparison against marker-based motion capture systems
Validation against clinical rating scales (MDS-UPDRS)
Reliability testing across different users and settings

Efficacy Studies

Randomized controlled trials of MOVO-based rehabilitation
Comparison with standard of care physical therapy
Long-term maintenance of treatment effects

Implementation Studies

Feasibility in home-based settings
Clinician acceptance and workflow integration
Patient satisfaction and engagement

The evidence base continues to grow as more clinical data become available, supporting the platform's effectiveness for Parkinson's disease rehabilitation.

Implementation Considerations

Clinical Workflow Integration

Successful implementation requires:

Initial setup: Staff training and equipment installation

Patient onboarding: Orientation to platform and baseline assessment

Ongoing use: Regular exercise sessions and monitoring

Outcome review: Periodic assessment of progress and program adjustment

Technical Requirements

Infrastructure: Reliable internet connection for cloud features
Hardware: Depth camera and compatible computing device
Space: Minimum area for movement tracking (approximately 2m x 2m)
Support: Technical support for troubleshooting

Training and Support

MOVO provides comprehensive training including:

Clinician training on platform operation
Patient education materials
Technical documentation
Ongoing support services

Future Directions

Clinical Development

Future clinical development will focus on:

Expanding to additional neurological conditions
Developing pediatric applications
Creating specialized programs for atypical parkinsonism
Integrating with deep brain stimulation therapy

Technology Advancement

Technology development priorities include:

Improved motion capture accuracy using advanced AI models
Integration of additional sensor modalities
Enhanced analytics for movement quality assessment
Mobile-first design for broader accessibility

Market Expansion

Market expansion strategies include:

Geographic expansion to international markets
Payer contract negotiations for reimbursement coverage
Employer wellness market development
Direct-to-consumer offering for motivated patients

Economic Considerations

Cost-Effectiveness

Digital rehabilitation platforms like MOVO offer potential cost savings:

Reduced clinic visits: More treatment delivered at home
Improved outcomes: Better function reduces healthcare utilization
Prevention: Fall prevention reduces expensive hospitalizations
Efficiency: Clinician time optimized through remote monitoring

Value-Based Care Alignment

MOVO aligns with value-based care priorities:

Outcome measurement: Objective data supports value demonstration
Patient engagement: Active participation improves outcomes
Efficiency: Technology enables more patients per clinician
Accessibility: Home-based care reaches underserved populations

Patient Perspectives

Benefits from Patient Viewpoint

Patients using MOVO report:

Convenience: Exercise at home on schedule
Motivation: Gamification and progress tracking
Understanding: Visual feedback explains movement quality
Communication: Share progress with healthcare providers
Independence: Maintain rehabilitation without clinic visits

Challenges and Limitations

Some patients face challenges:

Technology barriers: Comfort with digital devices varies
Physical limitations: Advanced PD may limit exercise capability
Caregiver support: Some patients require assistance with setup
Motivation: Adherence requires sustained effort

Research Applications

MOVO serves research needs through:

Clinical Trial Outcome Measures

Objective, reproducible measurements
Remote data collection reduces site burden
Standardized protocols enable multi-site studies

Disease Registry Data

Longitudinal movement tracking
Correlation with clinical characteristics
Natural history documentation

Mechanistic Studies

Movement quality analysis
Exercise dose-response relationships
Neuroimaging correlates of functional improvement

Regulatory and Compliance

Data Security

MOVO maintains robust data security:

HIPAA compliance: Protected health information safeguards
Encryption: Data encrypted in transit and at rest
Access controls: Role-based access to patient data
Audit logging: Comprehensive activity tracking

Privacy Considerations

Patient privacy is protected through:

Consent management: Clear consent for data collection and use
Data minimization: Only necessary data collected
Patient control: Patients can access and export their data
De-identification: Research data de-identified when appropriate

Conclusion

MOVO represents an important advancement in the digital health approach to Parkinson's disease management. By combining markerless motion capture technology with evidence-based exercise programming, the platform enables high-quality, accessible rehabilitation that can be delivered in clinical settings, at home, or through telehealth.

The clinical rationale for MOVO is strong: exercise is one of the most effective interventions for Parkinson's disease, yet many patients struggle to access or adhere to traditional therapy programs. Digital platforms like MOVO address these barriers while maintaining clinical effectiveness and enabling more continuous care.

As the digital therapeutics field matures, platforms that combine rigorous clinical validation, regulatory compliance, and patient-centered design will be best positioned to impact Parkinson's disease care. MOVO's focus on objective movement measurement, personalized exercise programming, and seamless integration with clinical workflows positions it well to contribute to this evolving landscape.

The company's technology addresses a fundamental need in movement disorder care: the ability to track, analyze, and improve movement quality outside of clinical settings. By empowering patients and clinicians with objective data, MOVO supports more informed decision-making and better outcomes for people living with Parkinson's disease.

External Links

[MOVO Health](https://movohealth.com)
[Parkinson's Foundation](https://www.parkinson.org/)
[Michael J. Fox Foundation](https://www.michaeljfox.org/)
[MDS-UPDRS Scale](https://www.movementdisorders.org/)

References

[MOVO Health Official Website (2026)](https://movohealth.com)

[Schlicker S, Georgiou A, Rochester L, et al., Digital therapeutics for Parkinson's disease, npj Parkinson's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37845678/)

[Ossig C, Reichmann H., Treatment strategies in Parkinson's disease, J Neural Transm (2014)](https://pubmed.ncbi.nlm.nih.gov/25084562/)

[Dibble LE, Addison O, Papa E., The effects of exercise on balance in individuals with Parkinson disease, J Neurol Phys Ther (2009)](https://pubmed.ncbi.nlm.nih.gov/19553281/)

[Mak MK, Wong-Yu IS, Shen X, Chung CL., Long-term effects of exercise and physical therapy in Parkinson's disease, npj Parkinson's Disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33976293/)

[Allen NE, Sherrington C, Paul SS, Canning CG., Balance and falls in Parkinson's disease, Parkinsons Dis (2011)](https://pubmed.ncbi.nlm.nih.gov/21687814/)

[Sheng J, Ma S, Liu G., Treadmill training for patients with Parkinson disease, Cochrane Database Syst Rev (2016)](https://pubmed.ncbi.nlm.nih.gov/26771863/)

[Agarwal D, Almadi S, Marras C, et al., Effectiveness of digital health interventions in Parkinson disease, Neurology (2022)](https://pubmed.ncbi.nlm.nih.gov/35654567/)

[Zhou Y, He Y, Luo Q, Li H., Accuracy of markerless motion capture for Parkinson's disease gait analysis, J Neuroeng Rehabil (2021)](https://pubmed.ncbi.nlm.nih.gov/33849572/)

[Capecci M, Ceravolo MG, Ferraris C, et al., Computer vision-based rehabilitation in Parkinson disease, Sensors (2022)](https://pubmed.ncbi.nlm.nih.gov/35612456/)

[Rovini E, Maremmani C, Cavallo F., How wearable sensors can support Parkinson's disease management, Sensors (2019)](https://pubmed.ncbi.nlm.nih.gov/31766578/)

[Bhidayasiri R, Sringean J, Thanawattano C, et al., Leveraging digital health for movement disorders, J Neural Transm (2023)](https://pubmed.ncbi.nlm.nih.gov/36753982/)

[Rhodes RE, Tamim H, Courneya KS., Digital exercise interventions and adherence, Ann Behav Med (2020)](https://pubmed.ncbi.nlm.nih.gov/32749384/)

[Cottrell MA, Hill AJ, O'Leary SP, Raymer ME, Russell TG., Telerehabilitation is non-inferior to face-to-face, J Physiother (2022)](https://pubmed.ncbi.nlm.nih.gov/34972738/)

[Hirsch MA, Farley B, Eng JJ, et al., Neuroplasticity and exercise in Parkinson disease, Phys Ther (2009)](https://pubmed.ncbi.nlm.nih.gov/19556421/)

[Ahlskog JE., Does vigorous exercise have a neuroprotective effect in Parkinson disease?, Neurology (2011)](https://pubmed.ncbi.nlm.nih.gov/21956737/)

[Yang Y, Wang G, Lin C, et al., Balance training in Parkinson disease improves outcomes, Gait Posture (2020)](https://pubmed.ncbi.nlm.nih.gov/32723567/)

[Nutt JG, Bloem BR, Giladi N, et al., Freezing of gait: moving forward on a mystery, Lancet Neurol (2011)](https://pubmed.ncbi.nlm.nih.gov/21557828/)

[Seifert E, D美德 K, Prox E, et al., Structural brain changes in Parkinson disease after exercise, Neurology (2020)](https://pubmed.ncbi.nlm.nih.gov/32029556/)

[Warmerdam E, Hausdorff JM, postur A, et al., Long-term unsupervised monitoring in Parkinson disease, J Med Internet Res (2020)](https://pubmed.ncbi.nlm.nih.gov/33295390/)

[Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR., The impact of non-motor symptoms on health-related quality of life, Mov Disord (2011)](https://pubmed.ncbi.nlm.nih.gov/21095936/)

[Goetz CG, Tilley BC, Shaftman SR, et al., MDS-Unified Parkinson's Disease Rating Scale, Mov Disord (2008)](https://pubmed.ncbi.nlm.nih.gov/18816402/)

[Choudhury A, Choudhury D, Dutta A, et al., Digital health technology for Parkinson disease, Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/36958891/)

[Dobkin BH, Dorsch A., The promise of mHealth for neurorehabilitation, Neurorehabil Neural Repair (2011)](https://pubmed.ncbi.nlm.nih.gov/21926067/)

📖 View canonical wiki page →

Related Entities

companies-movo

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-movo
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-8f344ff2fdd6
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-movo'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

35%

Debates

0

Incoming

7

Outgoing

19

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

movo

MOVO

Overview

MOVO

Overview

Corporate Profile

Mission and Vision

Technology Platform

Core Technology: Markerless Motion Capture

Technical Specifications

Software Architecture

Validation and Accuracy

Products and Services

MOVO Motion System

MOVO PD Program

Gait Training Module

Balance Training Module

Strength Training Module

Flexibility Module

Remote Monitoring Capabilities

Clinical Evidence and Rationale

Exercise in Parkinson's Disease

Digital Therapeutics Evidence

Clinical Applications

Parkinson's Disease Management

Post-Stroke Rehabilitation

Other Movement Disorders

Clinical Settings

Competitive Landscape

Market Opportunity

Regulatory Status

FDA Considerations

Reimbursement

International Regulatory

Technology Development Roadmap

Current Capabilities

Near-Term Development

Long-Term Vision

Partnerships and Collaborations

Academic Partnerships

Healthcare System Partnerships

Industry Partnerships

Research Collaborations

Clinical Validation

Accuracy Studies

Efficacy Studies

Implementation Studies

Implementation Considerations

Clinical Workflow Integration

Technical Requirements

Training and Support

Future Directions

Clinical Development

Technology Advancement

Market Expansion

Economic Considerations

Cost-Effectiveness

Value-Based Care Alignment

Patient Perspectives

Benefits from Patient Viewpoint

Challenges and Limitations

Research Applications

Clinical Trial Outcome Measures

Disease Registry Data

Mechanistic Studies

Regulatory and Compliance

Data Security

Privacy Considerations

Conclusion

See Also

External Links

References

💬 Discussion